Cargando…
Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
The monoclonal anti-CEA antibody, A5B7, has previously been administered to patients for radioimmunotherapy (RIT). Long circulation time and the formation of an immune response have limited therapeutic success in the clinic. Antibody fragments can be used to reduce the in vivo circulation time, but...
Autores principales: | Casey, J. L., King, D. J., Chaplin, L. C., Haines, A. M., Pedley, R. B., Mountain, A., Yarranton, G. T., Begent, R. H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074792/ https://www.ncbi.nlm.nih.gov/pubmed/8912535 |
Ejemplares similares
-
Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
por: Casey, J L, et al.
Publicado: (2002) -
Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments
por: Casey, J L, et al.
Publicado: (1999) -
Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
por: Delgado, C., et al.
Publicado: (1996) -
Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.
por: Casey, J. L., et al.
Publicado: (1998) -
Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
por: Obonai, Toshifumi, et al.
Publicado: (2016)